Whole-body CD8<sup>+</sup> T cell visualization before and during cancer immunotherapy: a phase 1/2 trial.

Nat Med · 2022 · PMC9800278 · PMID 36471036

Europe PMC DOI

hedged sentences

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

showed a trendP = 0.058so close (0.05 < p ≤ 0.1)

Patients with an above-median baseline 89 ZED88082A-uptake geometric mean SUV max (that is, >5.2) showed a trend towards superior progression-free survival (PFS) (median 1.5, 95% CI 1.3 to not reached; versus 3.9, 95% CI 2.6 to not reached, P = 0.058) and had superior overall survival (OS) to patients with an uptake below the median (median 6.5, 95% CI 3.3 to not reached, versus 13.8, 95% CI 11.3 to not reached, P = 0.030) (Fig. 4 ).

also in 53,322 other papers

a positive trendno p-value reported

Baseline tracer tumor uptake showed a positive trend with best overall response evaluation criteria in solid tumours (RECIST) response ( P trend = 0.064, Extended Data Fig. 6a ), and uptake was 40% (95% CI 0–94%) higher in patients with SD/PR/CR as best overall response during ICI ( P = 0.040; Extended Data Fig. 6b,c ).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.